Pharmaniaga Berhad has entered into a Memorandum of Understanding with CSPC Holdings Company Limited to establish a basis of cooperation and collaboration on pharmaceutical and biopharmaceutical products.
CSPC Pharmaceutical Group Limited is a leading pharmaceutical group in China, listed on the Main Board of the Hong Kong Stock Exchange since 1994 focusing on two business segments of finished drugs and bulk drugs, with innovative drugs as
the core development strategy. The group currently has a strong product portfolio in the therapeutic areas of nervous system disease, oncology, anti-infective and cardiovascular disease. It has an international R&D team with bases in Shijiazhuang, Shanghai, Beijing, and the United States, focusing on the discovery, research, and development of small molecule targeted drugs, nanodrugs, monoclonal antibody drugs, bispecific antibody drugs, antibody-drug conjugates, and biological drugs in the immune field.
CSPC is engaged in the business of research and development, manufacturing, and distribution of pharmaceutical, biological, and mRNA vaccine products.
Pharmaniaga sees the collaboration a platform to strengthen its research & development, manufacturing and commercialisation of innovative pharmaceutical and biopharmaceutical products segment.
